Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review

Document Sample
Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					          Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis
                                           Review
        Reference Code: GDPH34546FSA                                                                                             Publication Date: MAR 2013

          3101 Western Avenue, Suite 600                     Phone              +1 206 2827100                      Revenue          NA
          Seattle, WA                                        Fax                +1 206 2846206                      Net Profit       -62.36 (million USD)
          98119                                              Website            www.celltherapeutics.com            Employees        111
                                                                                                                                     Pharmaceuticals           &
          United States                                      Exchange           CTIC [NASDAQ]                       Industry
                                                                                                                                     Healthcare

       Company Overview
       Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company. It develops and commercializes integrated portfolio of oncology
       products. The company's product pipeline include Pixuvri (pixantrone dimaleate), is under development for the treatment of non-
       Hodgkin lymphoma (NHL); Tosedostat, is in Phase II clinical trial for the treatment of acute myeloid leukemia (AML) and
       myelodysplasia (MDS); Brostallicin, being studied for the treatment of triple-negative metastatic breast cancer in Phase II and III;
       Novel Bisplatinum Analogues; Opaxio (paclitaxel poliglumex), for the treatment of solid tumors and Pacritinib, is in Phase II
       clinical trial for the treatment of myelofibrosis.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Cell Therapeutics, Inc., SWOT Analysis
         James A. Bianco, M.D.               Chief Executive Officer                  Strengths                                Weaknesses
         Jack W. Singer, M.D.                Director
                                                                                      Collaborative Agreements                 Lack of Manufacturing Facilities
         Dr. Phillip M. Nudelman             Chairman
                                                                                      Strong Technological Base                Sale of Zevalin
         John H. Bauer                       Director
         Vartan Gregorian, Ph.D.             Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                            Threats
        Research, GlobalData
                                                                                      Market Potential: Cancer                 Uncertain R&D Outcomes
       Share Data
                                                                                      Strong Base of Pipeline                  Intense Competition
         Cell Therapeutics, Inc.
                                                                                      Products
        Share Price (USD) as on 08-Mar-                                  1.30
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -3.53        GlobalData
        Market Cap (million USD)                                         126
        Enterprise Value (million USD)                                   117
        Shares Outstanding (million)                                       97
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 28, 2013         Cell Therapeutics Reports 2012 Results
                                                                                      Nov 01, 2012         Cell Therapeutics Reports Q3 2012 Results
                                                                                      Sep 19, 2012         Cell Therapeutics Regains Compliance With
                                                                                                           NASDAQ Minimum Bid Price Rule
                                                                                      Aug 01, 2012         Cell Therapeutics Reports Q2 2012 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT                                                                     Reference Code: GDPH34546FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                         Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Cell Therapeutics, Inc. - Key Facts..................................................................................................................................................... 5
       Cell Therapeutics, Inc. - Key Employees ............................................................................................................................................ 6
       Cell Therapeutics, Inc. - Key Employee Biographies .......................................................................................................................... 7
       Cell Therapeutics, Inc. - Major Products and Services ....................................................................................................................... 9
       Cell Therapeutics, Inc. - Pharmaceutical Pipeline Products Data..................................................................................................... 10
          Cell Therapeutics, Inc., Pipeline Products by Therapy Area ......................................................................................................... 10
          Cell Therapeutics, Inc., Pipeline Products by Development Phase .............................................................................................. 11
       Cell Therapeutics, Inc. - History ....................................................................................................................................................... 14
       Cell Therapeutics, Inc. - Company Statement .................................................................................................................................. 16
       Cell Therapeutics, Inc. - Locations And Subsidiaries ....................................................................................................................... 18
          Head Office ................................................................................................................................................................................... 18
          Other Locations & Subsidiaries ..................................................................................................................................................... 18
       Section 2 – Company Analysis ......................................................................................................................................................... 19
       Cell Therapeutics, Inc. - Business Description ................................................................................................................................. 19
       Cell Therapeutics, Inc. - Corporate Strategy .................................................................................................................................... 20
       Cell Therapeutics, Inc. - SWOT Analysis.......................................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          Cell Therapeutics, Inc. - Strengths ................................................................................................................................................ 21
             Strength - Collaborative Agreements ........................................................................................................................................ 21
             Strength - Strong Technological Base ....................................................................................................................................... 21
          Cell Therapeutics, Inc. - Weaknesses .......................................................................................................................................... 21
             Weakness - Lack of Manufacturing Facilities ............................................................................................................................ 21
             Weakness - Sale of Zevalin....................................................................................................................................................... 21
             Weakness - Legal Proceedings ................................................................................................................................................. 22
          Cell Therapeutics, Inc. - Opportunities .......................................................................................................................................... 22
             Opportunity - Market Potential: Cancer ..................................................................................................................................... 22
             Opportunity - Strong Base of Pipeline Products ........................................................................................................................ 22
             Opportunity - Changing Demographics ..................................................................................................................................... 23
          Cell Therapeutics, Inc. - Threats ................................................................................................................................................... 23
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 23
             Threat - Intense Competition ..................................................................................................................................................... 23
             Threat - Stringent Government Regulations .............................................................................................................................. 23
       Cell Therapeutics, Inc. - Key Competitors ........................................................................................................................................ 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30


Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT                                                                                                  Reference Code: GDPH34546FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ........................................................ 30
          Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ........................................................ 31
       Cell Therapeutics, Inc., Recent Deals Summary .............................................................................................................................. 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          Cell Therapeutics, Inc., Recent Developments ............................................................................................................................. 33
             Feb 28, 2013: Cell Therapeutics Reports 2012 Results ............................................................................................................ 33
             Nov 01, 2012: Cell Therapeutics Reports Q3 2012 Results ...................................................................................................... 34
             Sep 19, 2012: Cell Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Rule .............................................. 35
             Aug 01, 2012: Cell Therapeutics Reports Q2 2012 Results ...................................................................................................... 35
             Jun 14, 2012: Cell Therapeutics Appoints Steven Benner As Chief Medical Officer ................................................................. 36
             Apr 20, 2012: Cell Therapeutics Reports Q1 2012 Results ....................................................................................................... 36
             Mar 07, 2012: Cell Therapeutics Reports Q4 2011 Results ...................................................................................................... 36
       Section 6 – Appendix ....................................................................................................................................................................... 38
          Methodology ................................................................................................................................................................................. 38
          Ratio Definitions ............................................................................................................................................................................ 38
          About GlobalData ......................................................................................................................................................................... 42
          Contact Us .................................................................................................................................................................................... 42
          Disclaimer ..................................................................................................................................................................................... 42




Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT                                                                                                  Reference Code: GDPH34546FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 3
© GlobalData. This report is a licensed product and is not to be copied, r
				
DOCUMENT INFO
Description: Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company. It develops and commercializes integrated portfolio of oncology products. The company's product pipeline include Pixuvri (pixantrone dimaleate), is under development for the treatment of non-Hodgkin lymphoma (NHL); Tosedostat, is in Phase II clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplasia (MDS); Brostallicin, being studied for the treatment of triple-negative metastatic breast cancer in Phase II and III; Novel Bisplatinum Analogues; Opaxio (paclitaxel poliglumex), for the treatment of solid tumors and Pacritinib, is in Phase II clinical trial for the treatment of myelofibrosis.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.